<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Archiving and Interchange DTD v2.3 20070202//EN" "archivearticle.dtd">
<article article-type="research-article" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">J Cell Biol</journal-id><journal-title>The Journal of Cell Biology</journal-title><issn pub-type="ppub">0021-9525</issn><issn pub-type="epub">1540-8140</issn><publisher><publisher-name>The Rockefeller University Press</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">10037797</article-id><article-id pub-id-type="pmc">2132927</article-id><article-categories><subj-group subj-group-type="heading"><subject>Regular Articles</subject></subj-group></article-categories><title-group><article-title>The Vitronectin Receptor and its Associated CD47 Molecule Mediates Proinflammatory Cytokine Synthesis in Human Monocytes by Interaction with Soluble CD23 </article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Hermann</surname><given-names>P.</given-names></name><xref ref-type="aff" rid="N0x217af10N0x1dafa40">&#x0002a;</xref></contrib><contrib contrib-type="author"><name><surname>Armant</surname><given-names>M.</given-names></name><xref ref-type="aff" rid="N0x217af10N0x1dafa40">&#x0002a;</xref><xref ref-type="aff" rid="N0x217af10N0x1dafa40">&#x02021;</xref></contrib><contrib contrib-type="author"><name><surname>Brown</surname><given-names>E.</given-names></name><xref ref-type="aff" rid="N0x217af10N0x1dafa40">&#x02016;</xref></contrib><contrib contrib-type="author"><name><surname>Rubio</surname><given-names>M.</given-names></name><xref ref-type="aff" rid="N0x217af10N0x1dafa40">&#x0002a;</xref></contrib><contrib contrib-type="author"><name><surname>Ishihara</surname><given-names>H.</given-names></name><xref ref-type="aff" rid="N0x217af10N0x1dafa40">&#x0002a;</xref></contrib><contrib contrib-type="author"><name><surname>Ulrich</surname><given-names>D.</given-names></name><xref ref-type="aff" rid="N0x217af10N0x1dafa40">&#x000a7;</xref></contrib><contrib contrib-type="author"><name><surname>Caspary</surname><given-names>R.G.</given-names></name><xref ref-type="aff" rid="N0x217af10N0x1dafa40">&#x000a7;</xref></contrib><contrib contrib-type="author"><name><surname>Lindberg</surname><given-names>F.P.</given-names></name><xref ref-type="aff" rid="N0x217af10N0x1dafa40">&#x02016;</xref></contrib><contrib contrib-type="author"><name><surname>Armitage</surname><given-names>R.</given-names></name><xref ref-type="aff" rid="N0x217af10N0x1dafa40">&#x000a7;</xref></contrib><contrib contrib-type="author"><name><surname>Maliszewski</surname><given-names>C.</given-names></name><xref ref-type="aff" rid="N0x217af10N0x1dafa40">&#x000a7;</xref></contrib><contrib contrib-type="author"><name><surname>Delespesse</surname><given-names>G.</given-names></name><xref ref-type="aff" rid="N0x217af10N0x1dafa40">&#x0002a;</xref></contrib><contrib contrib-type="author"><name><surname>Sarfati</surname><given-names>M.</given-names></name><xref ref-type="aff" rid="N0x217af10N0x1dafa40">&#x0002a;</xref></contrib></contrib-group><aff id="N0x217af10N0x1dafa40"><label>&#x0002a;</label>Laboratoire Allergie, Centre de recherch&#x000e9; Louis-Charles Simard, Pavillon Notre-Dame, Centre Hospitalier Universit&#x000e9; de  Montr&#x000e9;al (CHUM), Montreal, Quebec H2L 4M1, Canada; <label>&#x02021;</label>Laboratory for Parasitic Diseases, National Institutes of Health,  Bethesda, Maryland 20892; <label>&#x000a7;</label>Immunex Research Development Corporation, Seattle, Washington 98101; and <label>&#x02016;</label>Division of  Infectious Diseases, Washington University, St. Louis, Missouri 63110</aff><author-notes><fn><p>Address all correspondence to Dr. M. Sarfati, University of Montreal,  Laboratoire Allergie (M4211-K), Centre de recherch&#x000e9; Louis-Charles Simard, Pavillon Notre-Dame, 1560 Sherbrooke St. East, Montreal, Quebec  H2L 4M1, Canada. Tel.: (514) 281-6000 ext. 6632. Fax: (514) 896-4753.</p></fn></author-notes><pub-date pub-type="ppub"><day>22</day><month>2</month><year>1999</year></pub-date><volume>144</volume><issue>4</issue><fpage>767</fpage><lpage>775</lpage><history><date date-type="received"><day>11</day><month>6</month><year>1998</year></date><date date-type="rev-recd"><day>2</day><month>12</month><year>1998</year></date></history><copyright-year>1999</copyright-year><abstract><p>The vitronectin receptor, &#x003b1;<sub>v</sub>&#x003b2;<sub>3</sub> integrin, plays  an important role in tumor cell invasion, angiogenesis,  and phagocytosis of apoptotic cells. CD47, a member of  the multispan transmembrane receptor family, physically and functionally associates with vitronectin receptor (VnR). Although vitronectin (Vn) is not a ligand of  CD47, anti-CD47 and &#x003b2;<sub>3</sub> mAbs suppress Vn, but not fibronectin (Fn) binding and function. Here, we show  that anti-CD47, anti-&#x003b2;<sub>3</sub> mAb and Vn, but not Fn, inhibit sCD23-mediated proinflammatory function  (TNF-&#x003b1;, IL-12, and IFN-&#x003b3; release). Surprisingly, anti-CD47 and &#x003b2;<sub>3</sub> mAbs do not block sCD23 binding to  &#x003b1;<sub>v</sub><sup>&#x0002b;</sup>&#x003b2;<sub>3</sub><sup>&#x0002b;</sup> T cell lines, whereas Vn and an &#x003b1;<sub>v</sub> mAb (clone  AMF7) do inhibit sCD23 binding, suggesting the VnR  complex may be a functional receptor for sCD23.  sCD23 directly binds &#x003b1;<sub>v</sub><sup>&#x0002b;</sup>&#x003b2;<sub>3</sub><sup>&#x0002b;</sup>/CD47<sup>&#x02212;</sup> cell lines, but coexpression of CD47 increases binding. Moreover,  sCD23 binds purified &#x003b1;<sub>v</sub> protein and a single human &#x003b1;<sub>v</sub>  chain CHO transfectant. We conclude that the VnR  and its associated CD47 molecule may function as a  novel receptor for sCD23 to mediate its proinflammatory activity and, as such, may be involved in the inflammatory process of the immune response.</p></abstract><kwd-group><kwd>CD47</kwd><kwd>CD23</kwd><kwd>vitronectin receptor</kwd><kwd>TNF-&#x003b1;</kwd><kwd>IFN-&#x003b3;</kwd></kwd-group></article-meta></front><body><p>T<sc>he</sc> vitronectin receptor (&#x003b1;<sub>v</sub>&#x003b2;<sub>3</sub>) is an ubiquitous receptor that interacts with several ligands, such as  vitronectin (Vn)<sup>1</sup>, fibronectin (Fn), osteopontin,  and metalloproteinase MMP-2 (for review see <xref ref-type="bibr" rid="B15">Felding-Habermann and Cheresh, 1993</xref>; <xref ref-type="bibr" rid="B9">Brooks et al., 1996</xref>). As a  consequence, this integrin plays a role in diverse biologic  processes such as cell migration, tumor invasion, bone resorption, angiogenesis, and immune responsiveness (<xref ref-type="bibr" rid="B20">Gladson and Cheresh, 1994</xref>). </p><p>During the process of inflammation, circulating human  monocytes are able to leave the blood by attaching to, and  migrating through, endothelial and subendothelial matrices to the site of injury. The vitronectin receptor (VnR)  &#x003b1;<sub>v</sub>&#x003b2;<sub>3</sub>, expressed on endothelial cells, is involved in the  transendothelial migration process (<xref ref-type="bibr" rid="B11">Brown and Lindberg,  1996</xref>) together with PECAM (CD31) (<xref ref-type="bibr" rid="B12">Buckley et al.,  1996</xref>) and CD47 (<xref ref-type="bibr" rid="B13">Cooper et al., 1995</xref>). When recruited at  the inflammatory or infected sites, phagocytes undergo a  number of physiological changes including increases in adhesiveness, production of reactive oxygen metabolites,  and augmentation in phagocytosis. Extracellular matrix  proteins containing RGD sequence peptides have been  shown to mediate some of these functions (<xref ref-type="bibr" rid="B22">Hynes, 1992</xref>),  especially activation of phagocytic burst (<xref ref-type="bibr" rid="B37">Zhou and Brown,  1993</xref>), and enhancement of ingestion of opsonized particles by monocytes (<xref ref-type="bibr" rid="B21">Gresham et al., 1989</xref>).</p><p>The CD47 Ag is a widely expressed 50-kD multispan  transmembrane protein component of the &#x003b1;<sub>v</sub>&#x003b2;<sub>3</sub> and leukocyte response integrin signaling complex, since its expression was shown to enhance Vn, but not Fn, binding and  function to a variety of cells (<xref ref-type="bibr" rid="B10">Brown et al., 1990</xref>; <xref ref-type="bibr" rid="B32">Rosales  et al., 1992</xref>; <xref ref-type="bibr" rid="B27">Lindberg et al., 1993</xref>). It was reported that  CD47 does not directly bind Vn, and CD47<sup>&#x02212;</sup> cell lines, expressing &#x003b1;<sub>v</sub>&#x003b2;<sub>3</sub>, failed to bind Vn-coated beads (<xref ref-type="bibr" rid="B29">Lindberg  et al., 1996b</xref>). Moreover, CD47 deficient mice rapidly died  of <italic>Escherichia coli</italic> peritonitis, a phenomenon directly correlated with a reduction in leukocyte activation in response to &#x003b2;<sub>3</sub>, but not &#x003b2;<sub>2</sub>, integrin ligation (<xref ref-type="bibr" rid="B28">Lindberg et al.,  1996a</xref>). The &#x003b1;<sub>v</sub>&#x003b2;<sub>3</sub>/CD47 trimolecular complex also participates in the resolution of inflammation by mediating phagocytosis of aging leukocytes undergoing apoptosis before  they disgorge their potentially harmful contents (<xref ref-type="bibr" rid="B34">Savill et  al., 1990</xref>). This process is potentiated by the synthesis of  proinflammatory cytokine such as GM-CSF, TNF-&#x003b1;, IL-1,  and IFN-&#x003b3; (<xref ref-type="bibr" rid="B31">Ren and Savill, 1995</xref>).</p><p>CD23 has been purported to play a role in inflammation  based upon its in vitro proinflammatory activity (<xref ref-type="bibr" rid="B1">Armant  et al., 1994</xref>; <xref ref-type="bibr" rid="B26">Lecoanet-Henchoz et al., 1995</xref>; <xref ref-type="bibr" rid="B8">Bonnefoy et  al., 1996</xref>; <xref ref-type="bibr" rid="B33">Sarfati, 1997</xref>) and the observation that soluble  CD23 (sCD23) levels increased in various chronic inflammatory disorders, including rheumatoid arthritis and systemic lupus erythematosus (<xref ref-type="bibr" rid="B23">Ikizawa et al., 1993</xref>; <xref ref-type="bibr" rid="B7">Bertero  et al., 1994</xref>). sCD23 (<xref ref-type="bibr" rid="B1">Armant et al., 1994</xref>; Leconaet-Henchoz et al., 1995) and CD23 ligation (<xref ref-type="bibr" rid="B8">Bonnefoy et al.,  1996</xref>) can trigger monokine release by human monocytes.  Our studies have demonstrated that sCD23-induced TNF-&#x003b1;  secretion costimulates IFN-&#x003b3; production by IL-2&#x02013;activated T cells cocultured with syngeneic monocytes in the  absence of T cell receptor ligation (<xref ref-type="bibr" rid="B2">Armant et al., 1995</xref>).</p><p>Here, we report a novel function for VnR and its associated CD47 molecule on monocytes, by demonstrating that  this trimolecular complex mediates proinflammatory cytokine synthesis via interaction with CD23. This may contribute to the perpetuation of the inflammatory process in  chronic disorders such as rheumatoid arthritis. In this disease, CD23, TNF-&#x003b1;, and VnR expression are found to be  locally elevated in the inflamed synovium (<xref ref-type="bibr" rid="B4">Ashton et al.,  1993</xref>; <xref ref-type="bibr" rid="B16">Feldman et al., 1996</xref>).</p><sec id="MaterialsMethods" sec-type="materials|methods"><title>Materials and Methods</title><sec><title>Cell Lines and Reagents</title><p>Human recombinant IL-2, kindly provided by Dr. D. Bron (Institut Bordet, Brussels, Belgium), was used at 20 U/ml; IL-15 was obtained from <named-content content-type="company" xlink:href="immunex">Immunex</named-content> and used at 200 ng/ml. Endotoxin-free (&#x0003c;15 pg/ml, as determined  by the chromogenic Limulus amebocyte lysate, QCL-1000, BioWhittaker  Inc.) affinity-purified sCD23 was prepared in our laboratory from CSN of  CHO cell line transfected with human cDNA encoding for aa 148&#x02013;321 of  the CD23 molecule. The concentration of 25 ng/ml sCD23 used throughout this study was selected on the basis of previously reported dose&#x02013; response curves (<xref ref-type="bibr" rid="B1">Armant et al., 1994</xref>). Jurkat T (&#x003b1;<sub>v</sub><sup>&#x0002b;</sup>&#x003b2;<sub>3</sub><sup>&#x0002b;</sup>), THP-1 (&#x003b1;<sub>v</sub><sup>&#x02212;</sup>&#x003b2;<sub>3</sub><sup>&#x02212;</sup>)  monocytic, Raji (&#x003b1;<sub>v</sub><sup>&#x0002b;</sup>&#x003b2;<sub>3</sub><sup>&#x02212;</sup>), and Bowes melanoma (&#x003b1;<sub>v</sub><sup>&#x0002b;</sup>&#x003b2;<sub>3</sub><sup>&#x0002b;</sup>) cell lines were  obtained from the American Type Culture Collection (ATCC). K562 and  K562 transfected with the cDNA encoding the full-length CR2 (K562-CR2) were a generous gift from Drs. A. Masumoto and D. Fearon (Johns  Hopkins University, Baltimore, MD). CD47 deficient Jurkat T cell line  and 0V10 ovarian carcinoma cell line were generated in Drs. E. Brown  and F. Lindberg's laboratory (Washington University, St. Louis, MO).  cDNA encoding for CD51 (&#x003b1;<sub>v</sub> chain) was a generous gift from Dr. E. Ruoslahti (Burnham Institute, La Jolla, CA). 10G2 mAb (IgM class) was produced in our laboratory following immunization of mice with Jurkat T  cells. Hybridomas producing anti-CD47 (clone B6H12) and anti-&#x003b2;<sub>3</sub>  (CD61) mAbs (clone AP3) were purchased at the ATCC. Anti-&#x003b1;<sub>v</sub>&#x003b2;<sub>3</sub>  (CD51/CD61, clone LM609), and anti-&#x003b1;<sub>v</sub> (CD51, clone LM142) were  kindly provided by Dr. Cheresh (Scripps Research Institute, La Jolla,  CA). Anti-&#x003b1;v (CD51, clone AMF7) and anti-CD47 (clone BRIC126,  CKm1) were purchased from Immunotech, Serotec Ltd., and Accurate  Chemical and Scientific Corp., respectively. RGDS and RGES peptides,  Vn, Fn, and thrombospondin (TSP) were obtained from <named-content content-type="company" xlink:href="gibco">GIBCO BRL</named-content>.</p></sec><sec><title>Expression Cloning of 10G2 Antigen (CD47)</title><p>COS cells were transfected using the DEAE dextran method, with an expression library derived from Jurkat cells (4 &#x000d7; 10<sup>5</sup> clones). Cells expressing the molecule recognized by the 10G2 mAb were immunoselected by  indirect panning using 10G2 and anti&#x02013;mouse IgM-coated plates. Specifically bound cells were lysed, plasmid DNA was isolated, amplified, and  retransfected into COS cells. Following an additional round of immunoselection and plasmid purification, pools of 150 clones each were transfected  into COS cells, which were subsequently screened for positivity by incubation with radiolabeled 10G2 mAb. Two rounds of screening resulted in  the isolation of a single 10G2-reactive clone.</p></sec><sec><title>Establishment of Stable CHO Transfectants</title><p>CHO cells were grown at 50% confluence in 150-cm<sup>2</sup> culture flasks in 5%  heat decomplemented FCS containing DME (<named-content content-type="company" xlink:href="gibco">GIBCO BRL</named-content>) supplemented with 2 mM glutamine, 100 IU penicillin, and 100 &#x003bc;g/ml streptomycin. Cells were harvested using versene solution (<named-content content-type="company" xlink:href="gibco">GIBCO BRL</named-content>) and  washed twice with pure DME. Cells were then resuspended at 11 &#x000d7; 10<sup>6</sup> cells/ ml, and 10<sup>7</sup> cells were incubated in a 0.4-cm electrotransfection cuvette  (BioRad Laboratories) for 10 min with 20 &#x003bc;g of pBJ&#x003b1;<sub>v</sub> (plasmid containing cDNA encoding the full-length &#x003b1;<sub>v</sub> molecule, CD51), in order to obtain  CHO cells expressing the &#x003b1;<sub>v</sub> molecules. Cells were then pulsed at 220 V  and 960 &#x003bc;F using a Gene Pulser (BioRad Laboratories). After another 10  min of incubation at room temperature, electroporated cells were grown  for 24 h in nonselective culture medium which was then replaced by complete DME containing 500 &#x003bc;g/ml active G418 (<named-content content-type="company" xlink:href="gibco">GIBCO BRL</named-content>). After 14 d  of culture, the pool of survivors was analyzed by flow cytometry, and  CHO cell line expressing &#x003b1;<sub>v</sub> was subsequently enriched by FACS<sup>&#x000ae;</sup> for the  5% highest stained cells using anti-CD51 mAb as primary antibody. After  four rounds of sorting, we obtained stable cell lines, namely CHO-51, containing &#x0003e;99% of CD51<sup>&#x0002b;</sup> cells.</p></sec><sec><title>Cell Separation and Culture Conditions</title><sec><title>Monocytes.</title><p>PBMC were isolated by density gradient centrifugation of heparinized blood from healthy volunteers using Lymphoprep (Nycomed).  Monocytes were prepared by cold aggregation as described in <xref ref-type="bibr" rid="B2">Armant et  al. (1995)</xref>. Monocyte purity was shown to be &#x0003e;95% using phycoerythrin-conjugated anti-CD14 mAb and flow cytometry (<named-content content-type="company" xlink:href="becton">Becton Dickinson</named-content> and  Co.). Cellular viability was &#x0003e;90% using trypan blue exclusion.</p></sec><sec><title>T Cells.</title><p>Enriched T cell populations were obtained from the monocyte-depleted PBMC by rosetting with AET-SRBC and treatment with ammonium chloride. To obtain highly purified T cells, rosette forming cells were  washed and incubated for 20 min at 37&#x000b0;C in Lympho-Kwik T (One  Lambda). Cell purity was assessed by flow cytometry (FACScan<sup>&#x000ae;</sup>; <named-content content-type="company" xlink:href="becton">Becton  Dickinson</named-content> and Co.) using phycoerythrin-conjugated anti-CD3 mAb (<named-content content-type="company" xlink:href="becton">Becton Dickinson</named-content> and Co.) and shown to be &#x0003e;98% in all cases.</p><p>Cultures were performed in complete serum-free HB101 medium (Irvine Scientific) supplemented with 2 mM glutamine, 1 mM sodium pyruvate, 10 mM Hepes, 100 IU penicillin, and 100 &#x003bc;g/ml streptomycin in the  presence of polymyxin B 10 &#x003bc;g/ml (<named-content content-type="company" xlink:href="sigma">Sigma Chemical Co.</named-content>). When cultured  alone, monocytes were incubated in 5 ml sterile Falcon tubes (<named-content content-type="company" xlink:href="becton">Becton  Dickinson</named-content> and Co.) at 2 &#x000d7; 10<sup>5</sup> cells/ml for cytokine measurement. For coculture experiments, T cells (10<sup>6</sup> cells/ml) were incubated with monocytes  (2 &#x000d7; 10<sup>5</sup> cells/ml) in 24-well Falcon plates.</p></sec></sec><sec><title>Cytofluorometric Analysis</title><p>For sCD23 binding, cells or cell lines were washed in HBSS (<named-content content-type="company" xlink:href="gibco">Gibco Laboratories</named-content>), resuspended in HB101 complete serum free medium containing  biotinylated sCD23 (B-sCD23; 50 ng/ml) in the absence or presence of  mAbs (CD47, CD51, CD51/CD61), soluble Vn or Fn (20 &#x003bc;g/ml), and  RGDS peptides (20 &#x003bc;g/ml). After 4&#x02013;6 h of incubation at 22&#x000b0;C, cells were  washed with PBS containing 3% BSA, and further incubated with phycoerythrin-streptavidin (<named-content content-type="company" xlink:href="becton">Becton Dickinson</named-content> and Co.). Cell viability assessed  by trypan blue exclusion was &#x0003e;85% before staining with fluorochrome.  Indirect immunofluorescence staining of cells or cell lines with different  mAbs was performed according to standard techniques (<xref ref-type="bibr" rid="B2">Armant et al.,  1995</xref>).</p></sec><sec><title>Lymphokine Determinations</title><p>IFN-&#x003b3;, TNF-&#x003b1;, IL-10, and IL-12 were measured exactly as described in  Armant et al. (<xref ref-type="bibr" rid="B1">1994</xref>, <xref ref-type="bibr" rid="B2">1995</xref>). IL-1&#x003b2;, IL-8, and PGE<sub>2</sub> were measured by  ELISA kits purchased from R &#x00026; D Systems, Inc.</p></sec><sec><title>Immunoprecipitation and Western Blot Analysis</title><p>Cells were lysed in PBS containing 1% NP-40 (NP-40/PBS) supplemented  with protease inhibitors. The lysate was purified on anti-&#x003b2;<sub>3</sub> affinity column, and the eluate was separated by SDS-PAGE (5%) under nonreducing conditions and transferred to PDVF membrane (<named-content content-type="company" xlink:href="millipore">Millipore Corp.</named-content>).  Nonspecific binding sites on the membrane were blocked with PBS containing 5% milk. The membrane was incubated with milk containing  B-BSA, B-sCD23, B-CD51 mAbs (clone AMF7 and LM142), or B-CD61  mAb. After overnight incubation, membrane was treated with avidin-DH  and biotinylated peroxidase complex (Vectastain, ABC kit, Vector Labs,  Inc.) followed by ECL detection reagent (Nycomed <named-content content-type="company" xlink:href="amersham">Amersham</named-content>).</p></sec><sec><title>Statistical Analysis</title><p>Paired <italic>t</italic> tests have been used to assess levels of significance (*<italic>P</italic> &#x0003c; 0.05;  **<italic>P</italic> &#x0003c; 0.01; ***<italic>P</italic> &#x0003c; 0.001).</p></sec></sec><sec id="Results"><title>Results</title><sec><title>10G2 mAb, Which Inhibits sCD23 Biological Activities,  Recognizes CD47 Ag</title><p>sCD23 displays potent proinflammatory activity by directly triggering monokine release from purified monocytes in the absence of costimulatory signals, such as bacterial antigens (LPS or SAC) or T cell&#x02013;dependent signal  (sCD40L; <xref ref-type="bibr" rid="B1">Armant et al., 1994</xref>, <xref ref-type="bibr" rid="B2">1995</xref>; <xref ref-type="bibr" rid="B26">Lecoanet-Henchoz  et al., 1995</xref>). Although CD21 (CR2) and CD11b (CR3)  were previously described as novel CD23 counterreceptors (<xref ref-type="bibr" rid="B5">Aubry et al., 1992</xref>; Leconaet-Henchoz et al., 1995),  we also detected binding of sCD23 to several T cell lines  lacking CR2 or CR3 expression (<xref ref-type="bibr" rid="B25">Ishihara et al., 1995</xref>; Table <xref ref-type="table" rid="TI">I</xref>). In an effort to identify sCD23 binding component,  we generated mAbs to Jurkat T cells. We identified one  mAb, clone 10G2, which neutralized sCD23 biological activities (Fig. <xref ref-type="fig" rid="F1">1</xref> A), and displayed similar cell reactivity as  sCD23 (Table <xref ref-type="table" rid="TI">I</xref>). Specifically, 10G2 mAb, like sCD23, did  not stain the CD11b<sup>&#x0002b;</sup> (CR3) and CD11c<sup>&#x0002b;</sup> (CR4) THP-1  cell line. It recognized weakly, but with similar intensity,  K562 and K562-CR2 cell lines. 10G2 mAb also stained peripheral blood T, B cells, and monocytes (Table <xref ref-type="table" rid="TI">I</xref>). 10G2  mAb significantly suppressed sCD23 costimulation of  IFN-&#x003b3; production by IL-2&#x02013;stimulated T cells cocultured  with autologous monocytes (mean inhibition of 10 experiments, 66%, <italic>P</italic> &#x0003c; 0.03; Fig. <xref ref-type="fig" rid="F1">1</xref> A).  </p><p>The molecule recognized by 10G2 mAb was identified  by immunoaffinity panning of COS cells transfected with a  cDNA library prepared from Jurkat T cells. After several  rounds of selection, a single clone was selected which was  found by DNA sequencing to encode CD47 Ag (data not  shown). Results in Fig. <xref ref-type="fig" rid="F1">1</xref> B demonstrate binding of 10G2  to COS cells transfected with CD47 cDNA clone.</p><p>The effects of several anti-CD47 mAbs on sCD23 biological activity were examined (Fig. <xref ref-type="fig" rid="F1">1</xref> A). Besides the  10G2 mAb (IgM isotype), three other anti-CD47 mAbs of  different Ig isotype subclasses, C1Km1 (IgG1), BRIC126  (Ig2b), and B6H12 (IgG1) inhibited IFN-&#x003b3; production induced by sCD23 plus IL-2. These results support the notion that CD47 is part of the signaling complex triggered  by sCD23.</p><p>However, it appears that 10G2 was preferentially binding to a particular epitope on CD47. As depicted in Fig. <xref ref-type="fig" rid="F1">1</xref>  C, THP-1 cells express CD47 Ag but are not recognized by  10G2 mAb. Clone B6H12, a well-defined anti-CD47 mAb,  but not 10G2, stained THP-1 cell line in a dose-dependent  manner, while Jurkat T cells were recognized with similar  intensity by both anti-CD47 mAbs. There was no cross-inhibition of Jurkat staining by the two clones (data not  detailed). Our unpublished data also indicated that erythrocytes which expressed CD47 in the absence of integrins  (<xref ref-type="bibr" rid="B32">Rosales et al., 1992</xref>) were stained by B6H12 but not  10G2.</p></sec><sec><title>Anti-CD47 mAbs Suppress CD23 Costimulation of IL-12 and IFN-&#x003b3; Production Via Fc-independent Pathways</title><p>We investigated the mechanisms underlying the suppression of IFN-&#x003b3; production by anti-CD47 mAbs. In addition  to 10G2 mAb of the IgM isotype, the F(ab)&#x02032;<sub>2</sub> fragments of  B6H12 or intact BRIC126 mAb suppressed, in a dose-dependent manner, the ability of IL-2 and sCD23 to augment the production of IFN-&#x003b3; by T cells cocultured with  monocytes, demonstrating that the inhibition of IFN-&#x003b3; secretion by anti-CD47 mAb was not Fc-mediated (Fig. <xref ref-type="fig" rid="F2">2</xref>  A). Interestingly, IFN-&#x003b3; secretion by IL-2&#x02013;stimulated T  cells cocultured with monocytes and graded numbers of  CD23-transfected CHO cells, was also abrogated by anti-CD47 mAbs (Fig. <xref ref-type="fig" rid="F2">2</xref> B). </p><p>We previously reported in the presence of IL-2 or IL-15,  low levels of CD40L, expressed by unstimulated T cells,  were sufficient to engage CD40 on monocytes and trigger  IL-12 release. This monocyte-derived IL-12 production  synergized with IL-2 or IL-15 to augment IFN-&#x003b3; production by T cells (<xref ref-type="bibr" rid="B3">Armant et al., 1996</xref>; <xref ref-type="bibr" rid="B6">Avice et al., 1998</xref>). The  IFN-&#x003b3; response could be further amplified by sCD23-induced TNF-&#x003b1; release (<xref ref-type="bibr" rid="B2">Armant et al., 1995</xref>). Although  sCD23 did not trigger IL-12 production by purified monocytes (<xref ref-type="bibr" rid="B2">Armant et al., 1995</xref>), it costimulated IFN-&#x003b3; and IL-12  release in this coculture system, and the secretion of both  cytokines was strongly inhibited by anti-CD47 mAbs (Fig.  <xref ref-type="fig" rid="F2">2</xref>, C and D). </p></sec><sec><title>Anti-CD47 mAb Suppresses sCD23-induced Monokine Release</title><p>Because sCD23 directly triggers TNF-&#x003b1; release by purified  monocytes (<xref ref-type="bibr" rid="B2">Armant et al., 1995</xref>), and monocytes express  CD47 (Table <xref ref-type="table" rid="TI">I</xref>), we examined the effect anti-CD47 mAb  had on sCD23-induced monokine release by monocytes.  Anti-CD47 mAb significantly suppressed the induction by  sCD23 of TNF-&#x003b1;, IL-1&#x003b2;, and PGE<sub>2</sub> without affecting IL-8  secretion (Fig. <xref ref-type="fig" rid="F3">3</xref>). The data (i.e., inhibition of TNF-&#x003b1; and  IL-12 production) provide a mechanism by which anti-CD47 mAb can suppress sCD23 costimulation of IFN-&#x003b3;  production. </p><p>However, anti-CD47 mAb, in the absence of sCD23 or  in the presence of LPS, did not modulate TNF-&#x003b1; production (Fig. <xref ref-type="fig" rid="F3">3</xref> A). Our unpublished observations revealed  that anti-CD47 mAb, used alone or in combination with  sCD23, did not induce the production of monocyte deactivators (such as IL-10 or TGF-&#x003b2;), nor did it modulate SAC-induced TNF-&#x003b1;, IL-6, or IL-10 release. These results support the hypothesis that anti-CD47 mAbs interfere with  the sCD23 signaling pathway without impairing general  monocyte function.</p></sec><sec><title>sCD23 and Vitronectin Share the Same Receptor: VnR/CD47 Complex</title><p>Several studies indicate that CD47 is physically and functionally associated with the vitronectin receptor, &#x003b1;<sub>v</sub>&#x003b2;<sub>3</sub>.  Both anti-CD47 and anti-&#x003b2;<sub>3</sub> (CD61) mAbs can block binding of Vn, but not Fn, to &#x003b1;<sub>v</sub>&#x003b2;<sub>3</sub>, even though Vn does not  bind to CD47 (<xref ref-type="bibr" rid="B10">Brown et al., 1990</xref>; <xref ref-type="bibr" rid="B27">Lindberg et al., 1993</xref>).  Therefore, we examined the biological effects of anti-&#x003b2;<sub>3</sub>  mAb and the natural ligands of VnR (Vn and Fn) on  sCD23 function. It is important to note that all cultures  were performed in HB101 serum-free medium to eliminate FCS as a source of Vn and Fn. The results (Fig. <xref ref-type="fig" rid="F4">4</xref>)  suggested that Vn and sCD23 might share the same receptor, namely VnR/CD47 complex. Anti-&#x003b2;<sub>3</sub> mAb suppressed  sCD23 function, as defined by TNF-&#x003b1; secretion and IFN-&#x003b3;  production (Fig. <xref ref-type="fig" rid="F4">4</xref> A, and data not shown). Furthermore,  soluble Vn, but not Fn, suppressed sCD23-induced TNF-&#x003b1;  release by purified monocytes (Fig. <xref ref-type="fig" rid="F4">4</xref> B). sCD23 and Vn  most likely bound to distinct epitopes on &#x003b1;<sub>v</sub>&#x003b2;<sub>3</sub>, since an  anti-&#x003b1;<sub>v</sub>&#x003b2;<sub>3</sub> mAb (clone LM609), which specifically inhibited  Vn binding and function (<xref ref-type="bibr" rid="B18">Gao et al., 1996a</xref>), and RGDS  peptide had no suppressive activity (Fig. <xref ref-type="fig" rid="F4">4</xref> A, and data not  shown). </p><p>We next investigated the ability of mAbs directed to the  VnR complex, anti-CD47, CD61 (&#x003b2;<sub>3</sub>) and &#x003b1;<sub>v</sub>&#x003b2;<sub>3</sub> (LM609)  mAbs, and natural ligands of VnR, Vn, Fn, and RGDS  peptides, to alter sCD23 binding to the Jurkat T cell line.  Unexpectedly, anti-CD47 mAbs, alone or in combination  (Fig. <xref ref-type="fig" rid="F5">5</xref> b), anti-CD61 (Fig. <xref ref-type="fig" rid="F5">5</xref> c), or anti-&#x003b1;<sub>v</sub>&#x003b2;<sub>3</sub> clone LM609  (not shown) did not inhibit sCD23 binding to Jurkat or  monocytes (Hermann, P., unpublished observations). Note  that sCD23 binding was specifically suppressed by anti-CD23 mAb (Fig. <xref ref-type="fig" rid="F5">5</xref> a). The data suggested ligation of the  CD47 or &#x003b2;<sub>3</sub> chain of the trimolecular complex by mAbs  could indirectly inhibit sCD23 function by providing a  negative signal to the target cells, or by modifying CD47  complex configuration without displacing the sCD23 molecule. We examined whether engagement of VnR/CD47  complex by its natural ligands would modify sCD23 binding. As shown in Fig. <xref ref-type="fig" rid="F5">5</xref> d, Vn, but not Fn or RGDS peptide  (not shown), significantly inhibited sCD23 binding, strongly  suggesting the VnR complex was involved in the secretion  of proinflammatory cytokine via interaction with sCD23. </p><p>The possible role of the &#x003b1;<sub>v</sub> chain (CD51) of VnR in  sCD23 binding was explored. Three anti-CD51 mAbs  were tested, and we found one anti-CD51 mAb (clone  AMF7) inhibited the interaction between sCD23 and  &#x003b1;<sub>v</sub><sup>&#x0002b;</sup>&#x003b2;<sub>3</sub><sup>&#x0002b;</sup> Jurkat T (Fig. <xref ref-type="fig" rid="F5">5</xref> e), as well as &#x003b1;<sub>v</sub><sup>&#x0002b;</sup>&#x003b2;<sub>3</sub><sup>&#x02212;</sup> Raji B cell  lines (Fig. <xref ref-type="fig" rid="F5">5</xref> f). Note that the Raji B cell line expresses the  &#x003b2;<sub>5</sub> integrin (data not shown). We postulated that sCD23  was binding to &#x003b1;<sub>v</sub> and not &#x003b2;<sub>3</sub> chain of the VnR, whereas &#x003b2;<sub>3</sub>  and CD47 chains were likely to be involved in the signaling of the trimolecular complex in monocytes because  anti-CD47 and anti-&#x003b2;<sub>3</sub> inhibited sCD23 function, but not  binding.</p></sec><sec><title>sCD23 Interacts with &#x003b1;<sub>v</sub>/CD51 and CD47 Coexpression  Increases its Binding</title><p>Next, we selected a melanoma cell line, strongly expressing &#x003b1;<sub>v</sub>&#x003b2;<sub>3</sub> to purify this integrin by affinity chromatography  using anti-&#x003b2;<sub>3</sub> (CD61) immobilized AFFi-gel. Western blot  analysis (Fig. <xref ref-type="fig" rid="F6">6</xref>) shows sCD23 (lane 6) reacted with a single band of &#x0223c;135 kD, displaying a similar migration pattern as molecular species recognized by a cocktail of anti-CD51 mAbs (lane 2). However, sCD23 did not appear to  bind purified &#x003b2;<sub>3</sub> (CD61) chain which was identified by  anti-CD61 mAb (lane 4), or purified recombinant CD47  (not shown). </p><p>To further support the hypothesis that sCD23 may directly interact with &#x003b1;<sub>v</sub> chain of the trimolecular complex,  we prepared CHO transfectants singly expressing human  &#x003b1;<sub>v</sub> chain (CHO-CD51). The results in Fig. <xref ref-type="fig" rid="F7">7</xref> demonstrated  sCD23 strongly bound to CHO-CD51 compared to untransfected cell line. Although CHO-CD51 transfectant  did not express human &#x003b2;<sub>3</sub> (CD61) chain, CHO cell lines  were reported to express rodent &#x003b2; chain integrins (<xref ref-type="bibr" rid="B27">Lindberg et al., 1993</xref>) which likely associated with the human  &#x003b1;<sub>v</sub> chain underlying the successful stable expression of  a single human integrin chain. Nevertheless, CHO cells  also expressed hamster CD47 which might contribute to  sCD23 binding to &#x003b1;<sub>v</sub>/CD51 on live cells as reported for Vn  binding to untransfected CHO cells (<xref ref-type="bibr" rid="B27">Lindberg et al.,  1993</xref>). To directly assess whether CD47 expression was required for sCD23 interaction with &#x003b1;<sub>v</sub>/CD51, we examined  sCD23 binding to human CD47 deficient cell lines. As  shown in Fig. <xref ref-type="fig" rid="F8">8</xref>, sCD23 bound to OV10 ovarian carcinoma  VnR<sup>&#x0002b;</sup>/CD47<sup>&#x02212;</sup> cell line demonstrating that CD47 was dispensable for sCD23 binding. Coexpression of CD47 further  increased its binding. A similar effect was seen on transfection of CD47<sup>&#x02212;</sup> Jurkat with CD47 (data not shown).  </p><p>Given that sCD23 was not binding to CD47<sup>&#x0002b;</sup>/&#x003b1;<sub>v</sub><sup>&#x02212;</sup> (THP-1  cell line; Fig. <xref ref-type="fig" rid="F8">8</xref>), but reacted with &#x003b1;<sub>v</sub><sup>&#x0002b;</sup>&#x003b2;<sub>3</sub><sup>&#x02212;</sup> (Raji cell line;  Fig. <xref ref-type="fig" rid="F5">5</xref> f), we concluded that sCD23 ligated &#x003b1;<sub>v</sub>/CD51. The  VnR complex (&#x003b1;<sub>v</sub>&#x003b2;<sub>3</sub>/CD47 and/or &#x003b1;<sub>v</sub>&#x003b2;<sub>x</sub>/CD47) was used as  a functional receptor for sCD23 to mediate its proinflammatory activity and, as such, may be involved in the inflammatory process of the immune response.</p></sec></sec><sec id="Discussion"><title>Discussion</title><p>Our results can be summarized in the schematic model  presented in Fig. <xref ref-type="fig" rid="F9">9</xref>. We first postulate (Fig. <xref ref-type="fig" rid="F9">9</xref> A) that  sCD23 and Vn have distinct recognition sites on the &#x003b1;<sub>v</sub>&#x003b2;<sub>3</sub>/ CD47 complex. sCD23 binds to &#x003b1;<sub>v</sub> (CD51) and Vn to &#x003b1;<sub>v</sub>&#x003b2;<sub>3</sub>  (CD51/CD61) conformational site. Binding of Vn may induce structural changes in the integrin complex leading to  the masking of sCD23 binding sites, and vice versa. This  hypothesis is based on observations that Vn, anti-&#x003b1;<sub>v</sub> mAb  (clone AMF7), but not clone LM609 (which specifically  recognizes Vn binding site), nor RGDS peptide inhibited  sCD23 binding and function (Figs. <xref ref-type="fig" rid="F4">4</xref> and <xref ref-type="fig" rid="F5">5</xref>), and sCD23 directly bound to &#x003b1;<sub>v</sub> chain (Figs. <xref ref-type="fig" rid="F6">6</xref>&#x02013;<xref ref-type="fig" rid="F8">8</xref>). However, CD47 was  not a direct ligand for sCD23 while its coexpression improved sCD23 binding to &#x003b1;<sub>v</sub>/CD51. sCD23 bound CD47  deficient cell lines, but failed to bind CD47 in the absence  of &#x003b1;<sub>v</sub>/CD51 integrin (THP-1 cell line, erythrocytes and recombinant CD47 protein; Fig. <xref ref-type="fig" rid="F8">8</xref>, and data not shown). </p><p>Secondly, (Fig. <xref ref-type="fig" rid="F9">9</xref>, B and C) CD47 or CD61 engagement  by mAbs prevents Vn binding (<xref ref-type="bibr" rid="B27">Lindberg et al., 1993</xref>) without displacing sCD23 molecule (Fig. <xref ref-type="fig" rid="F5">5</xref>) while these mAbs  inhibit both sCD23 (Figs. <xref ref-type="fig" rid="F2">2</xref>&#x02013;<xref ref-type="fig" rid="F4">4</xref>) and Vn function perhaps by  modifying &#x003b2;<sub>3</sub> conformation or signaling pathway. <xref ref-type="bibr" rid="B27">Lindberg  et al. (1993)</xref> indicated that anti-CD47 and anti-&#x003b2;<sub>3</sub> (CD61)  mAbs (directed against an epitope of &#x003b2;<sub>3</sub> located outside  the Vn binding site) inhibited Vn-opsonized particle binding and function. They also proposed the CD47 molecule  participated in the appropriate folding of &#x003b1;<sub>v</sub>&#x003b2;<sub>3</sub>, and modulated the affinity of &#x003b1;<sub>v</sub>&#x003b2;<sub>3</sub> for Vn (<xref ref-type="bibr" rid="B10">Brown et al., 1990</xref>; <xref ref-type="bibr" rid="B27">Lindberg et al., 1993</xref>). Vn-coated particles failed to bind to a  CD47 deficient cell line (<xref ref-type="bibr" rid="B29">Lindberg et al., 1996b</xref>) or to cells  isolated from CD47 deficient mice (<xref ref-type="bibr" rid="B28">Lindberg et al., 1996a</xref>),  while these cells expressed &#x003b1;<sub>v</sub>&#x003b2;<sub>3</sub>, demonstrating that CD47  is dispensable for VnR expression, but required for Vn  binding and function. Using truncated forms of CD47,  they also reported the interaction between the extracellular domain of CD47 (IgV) and &#x003b1;<sub>v</sub> integrins was sufficient  for Vn binding (<xref ref-type="bibr" rid="B29">Lindberg et al., 1996b</xref>).</p><p>It has been reported that adhesion of integrins to their  counterreceptors is a dynamic phenomenon regulated by  intracellular signal transduction pathways (<xref ref-type="bibr" rid="B14">Diamond and  Springer, 1994</xref>). Structural changes in the extracellular domains of integrins following mAb ligation may modify  ligand adhesiveness in inducing or inhibiting ligand binding (inside-out signaling), or may directly provide a negative signal to the cell (outside-in signaling), as proposed  here for anti-CD47 and anti-CD61 mAb-mediated inhibition of sCD23 function.</p><p>In agreement with this hypothesis, it was reported that  antibodies recognizing CD81, another member of multispan transmembrane receptors family, inhibited Fc&#x003b5;RI-mediated mast cell degranulation without affecting IgE  binding, receptor-mediated Ca<sup>2&#x0002b;</sup> release, or tyrosine phosphorylation (<xref ref-type="bibr" rid="B17">Fleming et al., 1997</xref>).</p><p>Therefore, we propose a novel function for VnR/CD47  complex in the regulation of inflammatory response. In  the absence of pathogen, ligation of VnR by sCD23 mediates monokine release such as TNF-&#x003b1; which enhances the  inflammatory process by triggering the cascade of proinflammatory cytokine secretion (IL-1, IL-6, GM-CSF . . .;  <xref ref-type="bibr" rid="B16">Feldman et al., 1996</xref>), and facilitates the elimination of  apoptotic cells (<xref ref-type="bibr" rid="B31">Ren and Savill, 1995</xref>). Both effects are  negatively regulated by the presence of Vn (Fig. <xref ref-type="fig" rid="F4">4</xref> B and  <xref ref-type="bibr" rid="B34">Savill et al., 1990</xref>). Vn is a glycoprotein which is synthesized in the liver and circulates in plasma at high concentration (200&#x02013;400 &#x003bc;g/ml). The insoluble form is localized  extravascularly and is associated with granulation tissue  areas in rheumatoid arthritis synovia (<xref ref-type="bibr" rid="B35">Seiffert et al., 1993</xref>).</p><p>It has been reported that &#x003b2;<sub>3</sub> complex signaling via CD47  affected &#x003b2;<sub>2</sub> (CD18/CD11b and CD18/CD11c) integrins  binding to their ligands (<xref ref-type="bibr" rid="B36">Van Strijp et al., 1993</xref>; <xref ref-type="bibr" rid="B24">Ishibashi  et al., 1994</xref>). Previous studies identified CD11b and CD11c  as novel ligands for sCD23 (<xref ref-type="bibr" rid="B26">Lecoanet-Henchoz et al.,  1995</xref>). Our study shows that sCD23 bound CD11<sup>&#x02212;</sup> cell  lines (Jurkat and CHO cells; Figs. <xref ref-type="fig" rid="F1">1</xref> and <xref ref-type="fig" rid="F8">8</xref>) failed to stain  the THP-1 (CD11<sup>&#x0002b;</sup>) cell line (Fig. <xref ref-type="fig" rid="F8">8</xref>), and anti-CD47 mAb  did not alter CD11b expression, or sCD23 binding on  monocytes (data not shown), indicating that sCD23 does  not interact with &#x003b2;<sub>2</sub> integrins. We currently have no explanation for these contradictory results.</p><p>Interestingly, our unpublished data indicating TSP, a  newly discovered CD47 ligand (<xref ref-type="bibr" rid="B19">Gao et al., 1996b</xref>), also suppressed sCD23 function, without directly triggering monokine release, further supporting our present model. The  absence of VnR-mediated monokine secretion following  engagement by Vn, Fn, or TSP does not exclude the possibility that other ligands (see review <xref ref-type="bibr" rid="B15">Felding-Habermann  and Cheresh, 1993</xref>; <xref ref-type="bibr" rid="B20">Gladson and Cheresh, 1994</xref>) would  share, with sCD23, its proinflammatory activity. Finally,  the ability of the anti-CD47 mAbs examined to inhibit the  function of sCD23 without interfering with the phagocytosis of senescent cells (<xref ref-type="bibr" rid="B34">Savill et al., 1990</xref>) may help in the  design of novel therapeutic strategies for chronic inflammatory disorders, such as rheumatoid arthritis, in which  CD23 and TNF-&#x003b1; are implicated (<xref ref-type="bibr" rid="B30">Plater-Zyberk and Bonnefoy, 1995</xref>; <xref ref-type="bibr" rid="B16">Feldman et al., 1996</xref>).</p></sec></body><back><sec sec-type="display-objects"><title>Figures and Tables</title><table-wrap position="float" id="TI"><label>Table I</label><caption><p>Cellular Distribution of 10G2 Antigen on Human Cell Lines </p></caption><table frame="hsides" rules="groups"><thead><tr><th colspan="5">Freshly isolated human leukocytes</th><th/><th colspan="5">Human cell lines</th></tr><tr><th/><th/><th>sCD23</th><th/><th>10G2</th><th/><th/><th/><th>sCD23</th><th/><th>10G2</th></tr></thead><tbody><tr><td/><td/><td><italic>MFI</italic></td><td/><td><italic>MFI</italic></td><td/><td/><td/><td><italic>MFI</italic></td><td/><td><italic>MFI</italic></td></tr><tr><td align="left">T cells</td><td/><td>&#x0002b;&#x0002b;&#x0002b;</td><td/><td>&#x0002b;&#x0002b;&#x0002b;&#x0002b;</td><td/><td align="left">T cell lines (Jurkat, CEM, HUT 78)</td><td/><td>&#x0002b;&#x0002b;</td><td/><td>&#x0002b;&#x0002b;&#x0002b;&#x0002b;</td></tr><tr><td align="left">B cells</td><td/><td>&#x0002b;&#x0002b;</td><td/><td>&#x0002b;&#x0002b;</td><td/><td align="left">B cell lines (RPMI 8226, Raji, WIL-2, Daudi)</td><td/><td>&#x0002b;&#x0002b;</td><td/><td>&#x0002b;&#x0002b;</td></tr><tr><td align="left">Monocytes</td><td/><td>&#x0002b;</td><td/><td>&#x0002b;</td><td/><td align="left">Monocyte cell lines (U937)</td><td/><td>&#x0002b;&#x0002b;</td><td/><td>&#x0002b;&#x0002b;</td></tr><tr><td align="left"/><td/><td/><td/><td/><td/><td align="left">THP-1</td><td/><td>&#x02212;</td><td/><td>&#x02212;</td></tr><tr><td align="left">Erythrocytes</td><td align="left"/><td>&#x02212;</td><td/><td>&#x02212;</td><td align="left"/><td align="left">Erythroleukemia cell lines (K562/K562-CR2)</td><td align="left"/><td>&#x0002b;</td><td/><td>&#x0002b;</td></tr></tbody></table><table-wrap-foot><fn><p>Range of mean fluorescence intensity (MFI) are indicated as follows: (&#x0002b;) 1&#x02013;5; (&#x0002b;&#x0002b;) 10&#x02013;15; (&#x0002b;&#x0002b;&#x0002b;) 20&#x02013;25; (&#x0002b;&#x0002b;&#x0002b;&#x0002b;) 25&#x02013;35.          &#x000a0;</p></fn></table-wrap-foot></table-wrap><fig position="float" id="F1"><label>Figure 1</label><caption><p>Clone 10G2 neutralizes sCD23 biological activities and  recognizes CD47 Ag. (A) Inhibition of sCD23 costimulation of  IFN-&#x003b3; production in T cell/monocyte cocultures by anti-CD47  mAbs (clones 10G2, B6H12, C1Km1, and BRIC126). Mean &#x000b1;  SD for 10G2 <italic>P</italic> &#x0003c; 0.03 (ten experiments) and for other mAbs <italic>P</italic> &#x0003c;  0.001 (five independent experiments). (B) 10G2 mAb staining of  untransfected (COS, dotted line) or CD47-transfected COS cell  line (COS-47, bold line). Control mAb staining of both cell lines:  (COS, thin line; COS-47, dashed line). (C) Fluorescence staining  of Jurkat T cell line (left) and THP-1 monocyte cell line (right)  by increasing concentrations of anti-CD47 mAbs (clones 10G2  and B6H12). One representative experiment out of three.</p></caption><graphic xlink:href="JCB9806057.f1"/></fig><fig position="float" id="F2"><label>Figure 2</label><caption><p>Anti-CD47 mAb inhibits CD23 costimulation of IFN-&#x003b3;  production. (A) Dose-dependent inhibition of IFN-&#x003b3; production  in IL-2 plus sCD23 stimulated coculture system by mAb clone  BRIC126 and F(ab&#x02032;)<sub>2</sub> fragments of mAb clone B6H12. One representative experiment out of two. (B) Anti-CD47 mAb (clone  B6H12) inhibition of IFN-&#x003b3; secretion by T cells cocultured with  autologous monocytes and increasing numbers of untransfected  or CD23-transfected CHO cells. Similar data were obtained using clone 10G2 in three independent experiments. (C and D)  Anti-CD47 mAbs (clone B6H12) mediated inhibition of IFN-&#x003b3;  and IL-12 secretion in cocultures of IL-2&#x02013; or IL-15&#x02013;stimulated T  cells and autologous monocytes in the absence or presence of  sCD23. Mean &#x000b1; SD of six experiments. Anti-CD47 mAb inhibition in IL-2&#x02013; or IL-15&#x02013;stimulated cocultures, for IFN-&#x003b3; production <italic>P</italic> &#x0003c; 0.001, and <italic>P</italic> &#x0003c; 0.01 for IL-12 secretion.</p></caption><graphic xlink:href="JCB9806057.f2"/></fig><fig position="float" id="F3"><label>Figure 3</label><caption><p>Anti-CD47 mAb inhibition of sCD23-induced monokine release by purified monocytes. Monocytes (10<sup>6</sup>/ml) were cultured in the absence or presence of sCD23 or LPS with or without  anti-CD47 mAb (clone 10G2). After overnight cultures, TNF-&#x003b1;  (A), IL-1&#x003b2;, IL-8, or PGE<sub>2</sub> (B) was measured in the culture supernatant. Mean &#x000b1; SD of six experiments (*<italic>P</italic> &#x0003c; 0.05, **<italic>P</italic> &#x0003c; 0.01).</p></caption><graphic xlink:href="JCB9806057.f3"/></fig><fig position="float" id="F4"><label>Figure 4</label><caption><p>Suppression of sCD23-induced TNF-&#x003b1; release by anti-&#x003b2;<sub>3</sub> (CD61) mAb and Vn. sCD23-activated monocytes were cultured with anti-&#x003b2;<sub>3</sub> (CD61) clone AP3, anti-&#x003b1;<sub>v</sub>&#x003b2;<sub>3</sub> (CD51/CD61;  clone LM609), or isotype-matched mAbs (A) and with soluble  Vn or Fn (20 &#x003bc;g/ml, B). Mean &#x000b1; SD of four experiments (<italic>P</italic> &#x0003c;  0.01).</p></caption><graphic xlink:href="JCB9806057.f4"/></fig><fig position="float" id="F5"><label>Figure 5</label><caption><p>Effect of mAbs or natural ligands to VnR/CD47 complex on sCD23 binding to Jurkat and Raji cell lines. Jurkat  &#x003b1;<sub>v</sub><sup>&#x0002b;</sup>&#x003b2;<sub>3</sub><sup>&#x0002b;</sup> (CD51<sup>&#x0002b;</sup>/CD61<sup>&#x0002b;</sup>) (a&#x02013;e), or Raji &#x003b1;<sub>v</sub><sup>&#x0002b;</sup>&#x003b2;<sub>3</sub><sup>&#x02212;</sup> (CD51<sup>&#x0002b;</sup>/CD61<sup>&#x02212;</sup>)  (f) cell lines were stained by B-BSA (dotted line) or B-sCD23 in  the absence (solid line) or presence of the following inhibitors  (plain histograms): anti-CD23 mAb (a); anti-CD47 mAbs (cocktail of four anti-CD47 mAbs; b); anti-&#x003b2;<sub>3</sub> (CD61) mAb (c); Vn (d);  anti-&#x003b1;<sub>v</sub> (CD51) mAb (e and f). B-sCD23 plus isotype-matched  control mAb (a&#x02013;c, e, and f) or Fn (d) were shown as dashed lines.  One representative experiment out of four.</p></caption><graphic xlink:href="JCB9806057.f5"/></fig><fig position="float" id="F6"><label>Figure 6</label><caption><p>Western blot analysis of &#x003b1;<sub>v</sub><sup>&#x0002b;</sup>&#x003b2;<sub>3</sub><sup>&#x0002b;</sup> (CD51<sup>&#x0002b;</sup>/CD61<sup>&#x0002b;</sup>) melanoma cell line. Cell lysate was purified on anti-&#x003b2;<sub>3</sub> (CD61) mAb-affinity column. The eluate was separated by SDS-PAGE (5%)  and transferred to membrane. Staining by anti-&#x003b1;<sub>v</sub> (CD51) mAb  (clone AMF7 and LM142; lane 2), anti-&#x003b2;<sub>3</sub> (CD61, clone AP3;  lane 4), isotype-control matched mAbs (lanes 1 and 3), B-BSA  (lane 5), and B-sCD23 (lane 6) is shown.</p></caption><graphic xlink:href="JCB9806057.f6"/></fig><fig position="float" id="F7"><label>Figure 7</label><caption><p>Binding of sCD23 to CHO-51 (CHO &#x003b1;<sub>v</sub>) transfected  cell line. (A) &#x003b1;<sub>v</sub> (CD51)-transfected CHO cell line was stained  with (a) anti-CD47 mAbs (clones 10G2, solid line and B6H12,  dotted line) or isotype-matched control mAbs or with (b) anti-&#x003b1;<sub>v</sub>  (CD51) mAb (clone AMF7, dashed line) and anti-&#x003b2;<sub>3</sub> (CD61)  mAb (clone AP3, solid line), or isotype-matched cont mAbs. (B)  Untransfected (a), and &#x003b1;<sub>v</sub> (CD51)-transfected CHO cell lines (b)  were stained with B-sCD23 (plain histograms) or B-BSA (dotted  line). One representative experiment out of three.</p></caption><graphic xlink:href="JCB9806057.f7"/></fig><fig position="float" id="F8"><label>Figure 8</label><caption><p>Binding of sCD23 to  CD47<sup>&#x0002b;</sup> and CD47<sup>&#x02212;</sup> cell lines.  CD47<sup>&#x0002b;</sup> and CD47<sup>&#x02212;</sup> cell lines  were stained with two anti-CD47 mAbs (clone 10G2 and  B6H12), anti-&#x003b1;<sub>v</sub> (CD51) and  anti-&#x003b2;<sub>3</sub> (CD61) mAbs, or  B-sCD23 as described in Materials and Methods. OV10 carcinoma and Jurkat cell lines express different levels of &#x003b1;<sub>v</sub>  (CD51) chain which correlate  with sCD23 binding.</p></caption><graphic xlink:href="JCB9806057.f8"/></fig><fig position="float" id="F9"><label>Figure 9</label><caption><p>sCD23 and Vn share the same functional receptor,  VnR/CD47 complex. (A) sCD23 binds to &#x003b1;<sub>v</sub>/CD51 and Vn to  &#x003b1;<sub>v</sub>&#x003b2;<sub>3</sub> (CD51/CD61) conformational site while neither bind to  CD47. Binding of Vn to &#x003b1;<sub>v</sub>&#x003b2;<sub>3</sub> (CD51/CD61) obliterates sCD23  binding site, and vice versa. (B and C) Anti-CD47 and anti-&#x003b2;<sub>3</sub>  (CD61) mAbs suppress Vn binding and function (left) while they  inhibit sCD23 function, but not binding (right).</p></caption><graphic xlink:href="JCB9806057.f9"/></fig></sec><ack><p>We thank Dr. Y. Ohshima and Dr. C.E. Demeure for their help and criticism of the manuscript. The secretarial assistance of Norma Del Bosco is  greatly appreciated.</p><p>This work was supported by a grant from the Medical Research Council of Canada (MRC). Dr. M. Sarfati is supported by a MRC Scientist  Scholarship.</p></ack><glossary><title>Abbreviations used in this paper</title><def-list><def-item><term>B</term><def><p>biotinylated</p></def></def-item><def-item><term>Fn</term><def><p>fibronectin</p></def></def-item><def-item><term>sCD23</term><def><p>soluble CD23</p></def></def-item><def-item><term>TSP</term><def><p>thrombospondin</p></def></def-item><def-item><term>Vn</term><def><p>vitronectin</p></def></def-item><def-item><term>VnR</term><def><p>vitronectin receptor</p></def></def-item></def-list></glossary><ref-list><title>References</title><ref id="B1"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Armant</surname><given-names>M</given-names></name><name><surname>Ishihara</surname><given-names>H</given-names></name><name><surname>Rubio</surname><given-names>M</given-names></name><name><surname>Delespesse</surname><given-names>G</given-names></name><name><surname>Sarfati</surname><given-names>M</given-names></name></person-group><article-title>Regulation of cytokine production by soluble CD23: Costimulation of IFN-&#x003b3; secretion and triggering of TNF-&#x003b1; release</article-title><source>J Exp Med</source><year>1994</year><volume>180</volume><fpage>1005</fpage><lpage>1011</lpage><pub-id pub-id-type="pmid">8064221</pub-id></citation></ref><ref id="B2"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Armant</surname><given-names>M</given-names></name><name><surname>Rubio</surname><given-names>M</given-names></name><name><surname>Delespesse</surname><given-names>G</given-names></name><name><surname>Sarfati</surname><given-names>M</given-names></name></person-group><article-title>Soluble CD23 directly activates monocytes to contribute to the Ag-independent stimulation of resting T cells</article-title><source>J Immunol</source><year>1995</year><volume>155</volume><fpage>4868</fpage><lpage>4875</lpage><pub-id pub-id-type="pmid">7594490</pub-id></citation></ref><ref id="B3"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Armant</surname><given-names>M</given-names></name><name><surname>Armitage</surname><given-names>R</given-names></name><name><surname>Boiani</surname><given-names>N</given-names></name><name><surname>Delespesse</surname><given-names>G</given-names></name><name><surname>Sarfati</surname><given-names>M</given-names></name></person-group><article-title>Functional CD40 L expression on T lymphocytes in the absence of TCR engagement: involvement in IL-2-induced IL-12 and IFN&#x003b3; production</article-title><source>Eur J Immunol</source><year>1996</year><volume>26</volume><fpage>1430</fpage><lpage>1434</lpage><pub-id pub-id-type="pmid">8766543</pub-id></citation></ref><ref id="B4"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ashton</surname><given-names>BA</given-names></name><name><surname>Ashton</surname><given-names>IK</given-names></name><name><surname>Marshall</surname><given-names>MJ</given-names></name><name><surname>Butler</surname><given-names>RC</given-names></name></person-group><article-title>Localization of vitronectin receptor immunoreactivity and tartrate resistant acid phosphatase activity in synovium from patients with inflammatory or degenerative arthritis</article-title><source>Ann Rheum Dis</source><year>1993</year><volume>52</volume><fpage>133</fpage><lpage>137</lpage><pub-id pub-id-type="pmid">7680551</pub-id></citation></ref><ref id="B5"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Aubry</surname><given-names>J-P</given-names></name><name><surname>Pochon</surname><given-names>S</given-names></name><name><surname>Graber</surname><given-names>P</given-names></name><name><surname>Jansen</surname><given-names>KU</given-names></name><name><surname>Bonnefoy</surname><given-names>J-Y</given-names></name></person-group><article-title>CD21 is a ligand for CD23 and regulates IgE production</article-title><source>Nature</source><year>1992</year><volume>358</volume><fpage>505</fpage><lpage>507</lpage><pub-id pub-id-type="pmid">1386409</pub-id></citation></ref><ref id="B6"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Avice</surname><given-names>M-N</given-names></name><name><surname>Demeure</surname><given-names>CE</given-names></name><name><surname>Delespesse</surname><given-names>G</given-names></name><name><surname>Rubio</surname><given-names>M</given-names></name><name><surname>Armant</surname><given-names>M</given-names></name><name><surname>Sarfati</surname><given-names>M</given-names></name></person-group><article-title>IL-15 promotes IL-12 production by human monocytes via T  cell-dependent contact and may contribute to IL-12&#x02013;mediated IFN-&#x003b3; secretion by CD4<sup>&#x0002b;</sup>T cells in the absence of TCR ligation</article-title><source>J Immunol</source><year>1998</year><volume>161</volume><fpage>3409</fpage><lpage>3415</lpage></citation></ref><ref id="B7"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Bertero</surname><given-names>MT</given-names></name><name><surname>Converso</surname><given-names>M</given-names></name><name><surname>Aimo</surname><given-names>G</given-names></name><name><surname>Merico</surname><given-names>F</given-names></name></person-group><article-title>Serum levels of cytokines and soluble (s) CD23 in systemic lupus erythematosus</article-title><source>Fund Clin  Immunol</source><year>1994</year><volume>2</volume><fpage>37</fpage><lpage>43</lpage></citation></ref><ref id="B8"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Bonnefoy</surname><given-names>J-Y</given-names></name><name><surname>Plater-Zyberk</surname><given-names>C</given-names></name><name><surname>Lecoanet-Henchoz</surname><given-names>S</given-names></name><name><surname>Gauchat</surname><given-names>J-F</given-names></name><name><surname>Aubry</surname><given-names>J-P</given-names></name><name><surname>Graber</surname><given-names>P</given-names></name></person-group><article-title>A new role for CD23 in inflammation</article-title><source>Immunol Today</source><year>1996</year><volume>17</volume><fpage>418</fpage><lpage>420</lpage><pub-id pub-id-type="pmid">8854559</pub-id></citation></ref><ref id="B9"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Brooks</surname><given-names>PC</given-names></name><name><surname>Str&#x000f6;mblad</surname><given-names>S</given-names></name><name><surname>Sanders</surname><given-names>LC</given-names></name><name><surname>von Schalscha</surname><given-names>TL</given-names></name><name><surname>Aimes</surname><given-names>RT</given-names></name><name><surname>Stetler-Stevenson</surname><given-names>WG</given-names></name><name><surname>Quigley</surname><given-names>JP</given-names></name><name><surname>Cheresh</surname><given-names>DA</given-names></name></person-group><article-title>Localization of matrix metalloproteinase MMP-2 to the surface of invasive cells by interaction with integrin &#x003b1;v&#x003b2;3</article-title><source>Cell</source><year>1996</year><volume>85</volume><fpage>683</fpage><lpage>693</lpage><pub-id pub-id-type="pmid">8646777</pub-id></citation></ref><ref id="B10"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Brown</surname><given-names>E</given-names></name><name><surname>Hooper</surname><given-names>L</given-names></name><name><surname>Ho</surname><given-names>T</given-names></name><name><surname>Gresham</surname><given-names>H</given-names></name></person-group><article-title>Integrin-associated protein: a 50-kD plasma membrane antigen physically and functionally associated with integrins</article-title><source>J Cell Biol</source><year>1990</year><volume>6</volume><fpage>2785</fpage><lpage>2794</lpage><pub-id pub-id-type="pmid">2277087</pub-id></citation></ref><ref id="B11"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Brown</surname><given-names>EJ</given-names></name><name><surname>Lindberg</surname><given-names>FP</given-names></name></person-group><article-title>Leucocyte adhesion molecules in host defense against infection</article-title><source>Ann Med</source><year>1996</year><volume>28</volume><fpage>201</fpage><lpage>208</lpage><pub-id pub-id-type="pmid">8811163</pub-id></citation></ref><ref id="B12"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Buckley</surname><given-names>CD</given-names></name><name><surname>Doyonnas</surname><given-names>R</given-names></name><name><surname>Newton</surname><given-names>JP</given-names></name><name><surname>Blystone</surname><given-names>SD</given-names></name><name><surname>Brown</surname><given-names>EJ</given-names></name><name><surname>Watt</surname><given-names>SM</given-names></name><name><surname>Simmons</surname><given-names>DL</given-names></name></person-group><article-title>Identification of &#x003b1;v&#x003b2;3 as a heterotypic ligand for CD31/PECAM-1</article-title><source>J Cell Sci</source><year>1996</year><volume>109</volume><fpage>437</fpage><lpage>445</lpage><pub-id pub-id-type="pmid">8838667</pub-id></citation></ref><ref id="B13"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Cooper</surname><given-names>D</given-names></name><name><surname>Lindberg</surname><given-names>FP</given-names></name><name><surname>Gamble</surname><given-names>JR</given-names></name><name><surname>Brown</surname><given-names>EJ</given-names></name><name><surname>Vadas</surname><given-names>MA</given-names></name></person-group><article-title>Transendothelial migration of neutrophils involves integrin-associated protein (CD47)</article-title><source>Proc Natl Acad Sci USA</source><year>1995</year><volume>92</volume><fpage>3978</fpage><lpage>3982</lpage><pub-id pub-id-type="pmid">7732016</pub-id></citation></ref><ref id="B14"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Diamond</surname><given-names>MS</given-names></name><name><surname>Springer</surname><given-names>TA</given-names></name></person-group><article-title>The dynamic regulation of integrin adhesiveness</article-title><source>Curr Biol</source><year>1994</year><volume>4</volume><fpage>506</fpage><lpage>517</lpage><pub-id pub-id-type="pmid">7922371</pub-id></citation></ref><ref id="B15"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Felding-Habermann</surname><given-names>B</given-names></name><name><surname>Cheresh</surname><given-names>DA</given-names></name></person-group><article-title>Vitronectin and its receptors</article-title><source>Curr Opin Cell Biol</source><year>1993</year><volume>5</volume><fpage>864</fpage><lpage>868</lpage><pub-id pub-id-type="pmid">7694604</pub-id></citation></ref><ref id="B16"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Feldman</surname><given-names>M</given-names></name><name><surname>Brennan</surname><given-names>FM</given-names></name><name><surname>Maini</surname><given-names>RN</given-names></name></person-group><article-title>Role of cytokines in rheumatoid arthritis</article-title><source>Annu Rev Immunol</source><year>1996</year><volume>14</volume><fpage>397</fpage><lpage>440</lpage><pub-id pub-id-type="pmid">8717520</pub-id></citation></ref><ref id="B17"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Fleming</surname><given-names>TJ</given-names></name><name><surname>Donnadieu</surname><given-names>E</given-names></name><name><surname>Song</surname><given-names>CH</given-names></name><name><surname>Van Laethem</surname><given-names>F</given-names></name><name><surname>Galli</surname><given-names>SJ</given-names></name><name><surname>Kinet</surname><given-names>J-P</given-names></name></person-group><article-title>Negative regulation of Fc&#x003b5;RI-mediated degranulation by CD81</article-title><source>J Exp Med</source><year>1997</year><volume>186</volume><fpage>1307</fpage><lpage>1314</lpage><pub-id pub-id-type="pmid">9334370</pub-id></citation></ref><ref id="B18"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Gao</surname><given-names>A-G</given-names></name><name><surname>Lindberg</surname><given-names>FP</given-names></name><name><surname>Dimitry</surname><given-names>JM</given-names></name><name><surname>Brown</surname><given-names>EJ</given-names></name><name><surname>Frazier</surname><given-names>WA</given-names></name></person-group><article-title>Thrombospondin modulates &#x003b1;<sub>v</sub>&#x003b2;<sub>3</sub>function through integrin-associated protein</article-title><source>J Cell Biol</source><year>1996a</year><volume>135</volume><fpage>533</fpage><lpage>544</lpage><pub-id pub-id-type="pmid">8896608</pub-id></citation></ref><ref id="B19"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Gao</surname><given-names>A-G</given-names></name><name><surname>Lindberg</surname><given-names>FP</given-names></name><name><surname>Finn</surname><given-names>MB</given-names></name><name><surname>Blystone</surname><given-names>SD</given-names></name><name><surname>Brown</surname><given-names>EJ</given-names></name><name><surname>Frazier</surname><given-names>WA</given-names></name></person-group><article-title>Integrin-associated protein is a receptor for the C-terminal domain of thrombospondin</article-title><source>J Biol Chem</source><year>1996b</year><volume>271</volume><fpage>21</fpage><lpage>24</lpage><pub-id pub-id-type="pmid">8550562</pub-id></citation></ref><ref id="B20"><citation citation-type="other">Gladson, C.L., and D.A. Cheresh. 1994. The &#x003b1;v integrins. <italic>In</italic> Integrins: The Biological Problems. Y. Takoda, editor. CRC Press, Boca Raton, FL. 83&#x02013;99.</citation></ref><ref id="B21"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Gresham</surname><given-names>HD</given-names></name><name><surname>Goodwin</surname><given-names>JL</given-names></name><name><surname>Allen</surname><given-names>PM</given-names></name><name><surname>Anderson</surname><given-names>DC</given-names></name><name><surname>Brown</surname><given-names>EJ</given-names></name></person-group><article-title>A novel member of the integrin receptor family mediates Arg-Gly-Asp-stimulated neutrophil phagocytosis</article-title><source>J Cell Biol</source><year>1989</year><volume>108</volume><fpage>1935</fpage><lpage>1943</lpage><pub-id pub-id-type="pmid">2785522</pub-id></citation></ref><ref id="B22"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Hynes</surname><given-names>RO</given-names></name></person-group><article-title>Integrins: versatility, modulation and signaling in cell adhesion</article-title><source>Cell</source><year>1992</year><volume>69</volume><fpage>11</fpage><lpage>25</lpage><pub-id pub-id-type="pmid">1555235</pub-id></citation></ref><ref id="B23"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ikizawa</surname><given-names>K</given-names></name><name><surname>Yanagihara</surname><given-names>K</given-names></name><name><surname>Kajiwara</surname><given-names>T</given-names></name><name><surname>Koshio</surname><given-names>T</given-names></name><name><surname>Shida</surname><given-names>T</given-names></name><name><surname>Yamada</surname><given-names>A</given-names></name></person-group><article-title>Possible role of CD5<sup>&#x0002b;</sup>B cells expressing CD23 in mediating the elevation of serum soluble CD23 in patients with rheumatoid arthritis</article-title><source>Int Arch  Allergy Immunol</source><year>1993</year><volume>101</volume><fpage>416</fpage><lpage>424</lpage><pub-id pub-id-type="pmid">7689005</pub-id></citation></ref><ref id="B24"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ishibashi</surname><given-names>Y</given-names></name><name><surname>Claus</surname><given-names>S</given-names></name><name><surname>Relman</surname><given-names>DA</given-names></name></person-group><article-title><italic>Bordetella pertussis</italic>filamentous hemagglutinin interacts with a leukocyte signal transduction complex and stimulates bacterial adherence to monocyte CR3 (CD11b/CD18)</article-title><source>J Exp  Med</source><year>1994</year><volume>180</volume><fpage>1225</fpage><lpage>1233</lpage><pub-id pub-id-type="pmid">7931059</pub-id></citation></ref><ref id="B25"><citation citation-type="other">Ishihara, H., M. Rubio, G. Delespesse, and M. Sarfati. 1995. Soluble CD23 does  not react with complement receptor (CR2) antigen. <italic>In</italic> Leukocyte Typing V.  Shlossman, editors. Oxford University Press, New York. 536&#x02013;538.</citation></ref><ref id="B26"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Lecoanet-Henchoz</surname><given-names>S</given-names></name><name><surname>Gauchat</surname><given-names>J-F</given-names></name><name><surname>Aubry</surname><given-names>J-P</given-names></name><name><surname>Graber</surname><given-names>P</given-names></name><name><surname>Life</surname><given-names>P</given-names></name><name><surname>Paul-Eugene</surname><given-names>N</given-names></name><name><surname>Ferrua</surname><given-names>B</given-names></name><name><surname>Corbi</surname><given-names>AL</given-names></name><name><surname>Dugas</surname><given-names>B</given-names></name><name><surname>Plater-Zyberk</surname><given-names>C</given-names></name><etal/></person-group><article-title>CD23 regulates monocyte activation through a novel interaction with the adhesion molecules CD11b-CD18 and CD11c-CD18</article-title><source>Immunity</source><year>1995</year><volume>3</volume><fpage>119</fpage><lpage>125</lpage><pub-id pub-id-type="pmid">7621072</pub-id></citation></ref><ref id="B27"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Lindberg</surname><given-names>FP</given-names></name><name><surname>Gresham</surname><given-names>HD</given-names></name><name><surname>Schwarz</surname><given-names>E</given-names></name><name><surname>Brown</surname><given-names>EJ</given-names></name></person-group><article-title>Molecular  cloning of integrin-associated protein: an immunoglobulin family member  with multiple membrane-spanning domains implicated in &#x003b1;<sub>v</sub>&#x003b2;<sub>3</sub>-dependent ligand binding</article-title><source>J Cell Biol</source><year>1993</year><volume>123</volume><fpage>485</fpage><lpage>496</lpage><pub-id pub-id-type="pmid">7691831</pub-id></citation></ref><ref id="B28"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Lindberg</surname><given-names>FP</given-names></name><name><surname>Bullard</surname><given-names>DC</given-names></name><name><surname>Caver</surname><given-names>TE</given-names></name><name><surname>Gresham</surname><given-names>HD</given-names></name><name><surname>Beaudet</surname><given-names>AL</given-names></name><name><surname>Brown</surname><given-names>EJ</given-names></name></person-group><article-title>Decreased resistance to bacterial infection and granulocyte defects in IAP-deficient mice</article-title><source>Science</source><year>1996a</year><volume>274</volume><fpage>795</fpage><lpage>798</lpage><pub-id pub-id-type="pmid">8864123</pub-id></citation></ref><ref id="B29"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Lindberg</surname><given-names>FP</given-names></name><name><surname>Gresham</surname><given-names>HD</given-names></name><name><surname>Reinhold</surname><given-names>MI</given-names></name><name><surname>Brown</surname><given-names>EJ</given-names></name></person-group><article-title>Integrin-associated protein immunoglobulin domain is necessary for efficient vitronectin bead binding</article-title><source>J Cell Biol</source><year>1996b</year><volume>134</volume><fpage>1313</fpage><lpage>1322</lpage><pub-id pub-id-type="pmid">8794870</pub-id></citation></ref><ref id="B30"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Plater-Zyberk</surname><given-names>C</given-names></name><name><surname>Bonnefoy</surname><given-names>J-Y</given-names></name></person-group><article-title>Marked amelioration of established collagen-induced arthritis by treatment with antibodies to CD23 <italic>in  vivo. </italic></article-title><source>Nat Med</source><year>1995</year><volume>1</volume><fpage>781</fpage><lpage>785</lpage><pub-id pub-id-type="pmid">7585180</pub-id></citation></ref><ref id="B31"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ren</surname><given-names>Y</given-names></name><name><surname>Savill</surname><given-names>J</given-names></name></person-group><article-title>Proinflammatory cytokines potentiate thrombospondin-mediated phagocytosis of neutrophils undergoing apoptosis</article-title><source>J Immunol</source><year>1995</year><volume>154</volume><fpage>2366</fpage><lpage>2374</lpage><pub-id pub-id-type="pmid">7532668</pub-id></citation></ref><ref id="B32"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Rosales</surname><given-names>C</given-names></name><name><surname>Gresham</surname><given-names>HD</given-names></name><name><surname>Brown</surname><given-names>EJ</given-names></name></person-group><article-title>Expression of the 50-kD integrin-associated protein on myeloid cells and erythrocytes</article-title><source>J Immunol</source><year>1992</year><volume>149</volume><fpage>2759</fpage><lpage>2764</lpage><pub-id pub-id-type="pmid">1401911</pub-id></citation></ref><ref id="B33"><citation citation-type="other">Sarfati, M. 1997. CD23 workshop panel report. B7/608. <italic>In</italic> Leukocyte Typing  VI. T. Kishimoto, H. Kikutani, A. von dem Borne, S.M. Goyert, D.Y. Mason, M. Miyasaka, L. Moretta, K. Okumura, S. Shaw, T.A. Springer, et al.,  editors. Garland Publishing, Inc., New York. 144&#x02013;147.</citation></ref><ref id="B34"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Savill</surname><given-names>J</given-names></name><name><surname>Dransfield</surname><given-names>I</given-names></name><name><surname>Hogg</surname><given-names>N</given-names></name><name><surname>Haslett</surname><given-names>C</given-names></name></person-group><article-title>Vitronectin receptor-mediated phagocytosis of cells undergoing apoptosis</article-title><source>Nature</source><year>1990</year><volume>343</volume><fpage>170</fpage><lpage>173</lpage><pub-id pub-id-type="pmid">1688647</pub-id></citation></ref><ref id="B35"><citation citation-type="other">Seiffert, D., T.J. Podor, and D.J. Loskutoff. 1993. Distribution of vitronectin. <italic>In</italic>  Biology of Vitronectins and their Receptors. K.T. Preissner, S. Rosenblatt,  C. Kost, H. Wegerhoff, and D.F. Mosher, editors. Excerta Medica, Amsterdam/New York/London/Tokyo, 75.</citation></ref><ref id="B36"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Van Strijp</surname><given-names>JAG</given-names></name><name><surname>Russell</surname><given-names>DG</given-names></name><name><surname>Tuomanen</surname><given-names>E</given-names></name><name><surname>Brown</surname><given-names>EJ</given-names></name><name><surname>Wright</surname><given-names>SD</given-names></name></person-group><article-title>Ligand specificity of purified complement receptor type three (CD11b/ CD18, &#x003b1;m&#x003b2;2, Mac-1)</article-title><source>J Immunol</source><year>1993</year><volume>151</volume><fpage>3324</fpage><lpage>3336</lpage><pub-id pub-id-type="pmid">8376780</pub-id></citation></ref><ref id="B37"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Zhou</surname><given-names>M</given-names></name><name><surname>Brown</surname><given-names>EJ</given-names></name></person-group><article-title>Leukocyte response integrin and integrin-associated protein act as a signal transduction unit in generation of a phagocyte respiratory burst</article-title><source>J Exp Med</source><year>1993</year><volume>178</volume><fpage>1165</fpage><lpage>1174</lpage><pub-id pub-id-type="pmid">8104228</pub-id></citation></ref></ref-list><fn-group><fn><p>P. Hermann and M. Armant contributed equally to this study. </p></fn></fn-group></back></article>


